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component of the signaling pathways altered in
hypertension-related cardiac remodeling. However, in the
LIFE study and other related meta-analysis, antihypertensive
treatment with beta blocker-based therapy resulted in less
LVH regression than an ACEI or ARB-based strategy. The
diminished efficacy of beta-blockers on LVH reduction might
reside in their inability to decrease myocardial fibrosis. In
contrast, RD strategy has shown significant LVH regression
and improvement of diastolic function. It has also been noted
that RD-induced LVH regression was not exclusively associ-
ated with BP reduction.
However, the number of patients involved in this trial was
small and the follow up duration was only 6 months.
Furthermore, no comparator therapy was available for this
group of resistant hypertension patients. A role for the
sympathetic nervous system in long-term control of body
fluid volumes and arterial pressure is controversial for several
reasons, including the difficulty in assessing the functional
effects of the renal nerves under chronic conditions. A key
issue with this RF energy denervation approach is whether
anatomical and/or functional re-growth of renal sympathetic
nerves occur, abrogating the long term BP-lowering benefits.
Such re-growth has been observed in other conditions where
sympathetic nerves have been disrupted, such as in organ
transplantation. A large randomized controlled trial with
long-term follow up is required.
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ALTITUDE study
Background: Patientswith type 2 diabetes are at increased risk
of macro- and microvascular disease, and the presence of
albuminuria and/or reduced kidney function further
enhances macrovascular risk. ACEI reduce both macro- and
microvascular events, yet the residual renal and cardiovas-
cular risk still remains high. Aliskiren a novel oral direct renin
inhibitor that unlike ACEI and ARBs, lowers plasma renin
activity, angiotensin I and angiotensin II levels, may thereby
provide greater benefit compared to ACEI or ARB alone.
Methods: The primary objective of the ALTITUDE trial was
to determine whether aliskiren 300 mg once daily, reduces
cardiovascular and renal morbidity and mortality compared
with placebo when added to conventional treatment
(including ACEI or ARB). ALTITUDE was an international,
randomized, double-blind, placebo-controlled, parallel-group
study, which included three categories of high-risk patients
with type 2 diabetes (aged 35 years): those with either
urinary albumin/creatinine ratio (UACR) 200 mg/g; micro-
albuminuria (UACR)20<200mg/g and eGFR30<60mL/min/
1.73 m2; and thirdly, those with a history of cardiovascular
disease and eGFR 30<60 mL/min/1.73 m2 with or without
microalbuminuria. ALTITUDE was an event driven trial that
aimed to randomize 8600 patients with a planned follow-up
time of 48 months. The primary outcome measure was time
to first event for the composite endpoint of cardiovasculardeath, resuscitated death, myocardial infarction, stroke,
unplanned hospitalization for heart failure, onset of end-stage
renal disease or doubling of baseline serum creatinine
concentration. Secondary endpoints included a composite CV
endpoint and a composite renal endpoint.
Perspective
The trial was prematurely halted by data safety and moni-
toring board (DSMB) as there was an increase in adverse
events and no apparent benefits among patients randomized
to aliskiren.
In making its recommendation, the DSMB noted that
the active-treatment group experienced an increased
incidence of nonfatal stroke, renal complications, hyper-
kalemia, and hypotension over 18e24 months of follow-up.
The committee concluded that patients were unlikely to
benefit from aliskiren on top of standard antihypertensive
therapy.
Though earlier this year, ACCELERATE trial looking at
aliskiren in combination with a calcium-channel blocker
showed positive results and the FDA had approved both
a dual- and triple-combination drug including aliskiren, but
the recommended combination did not include an ACEI or
ARB.
ALTITUDE study tried to evaluate the effect of direct
renin inhibition in diabetic patients who are likely to
experience the compensatory rise in plasma renin and
other downstream RAAS components, including aldoste-
rone, induced by ACEI or ARBs. The damaging impact of
aldosterone escape is well established in CVD and renal
disease during ACEI or ARB treatment. Aliskiren was
expected to block the compensatory rise in RAAS activity,
and offer a novel approach to dual blockade of the RAAS.
Although recent results of both VALIANT and ONTARGET
showed no clinical benefits of the combination of effective
doses of an ACEI and ARB, it was presumed combining
either of them with aliskiren would offset potential dele-
terious effects of compensating rennin activation. However,
the results of ALTITUDE study showed the combination to
be detrimental.
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Objectives: Does coronary artery calcification (CAC) in
patients with cardiac symptoms correlate with severity of
